Equities analysts expect American Renal Associates Holdings Inc (NYSE:ARA) to post $0.15 earnings per share for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for American Renal Associates’ earnings, with the highest EPS estimate coming in at $0.16 and the lowest estimate coming in at $0.13. American Renal Associates reported earnings of $0.19 per share during the same quarter last year, which suggests a negative year over year growth rate of 21.1%. The business is expected to report its next quarterly earnings report on Tuesday, November 13th.

On average, analysts expect that American Renal Associates will report full-year earnings of $0.60 per share for the current year, with EPS estimates ranging from $0.56 to $0.65. For the next fiscal year, analysts forecast that the firm will post earnings of $0.62 per share, with EPS estimates ranging from $0.56 to $0.70. Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that follow American Renal Associates.

American Renal Associates (NYSE:ARA) last released its quarterly earnings results on Tuesday, August 7th. The company reported $0.20 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.17 by $0.03. American Renal Associates had a negative net margin of 1.11% and a positive return on equity of 19.60%. The firm had revenue of $217.18 million for the quarter, compared to the consensus estimate of $203.70 million.

Several equities research analysts recently issued reports on ARA shares. SunTrust Banks reaffirmed a “buy” rating and set a $25.00 price target on shares of American Renal Associates in a research note on Thursday. ValuEngine raised shares of American Renal Associates from a “hold” rating to a “buy” rating in a report on Friday, August 3rd. Bank of America decreased their price objective on shares of American Renal Associates from $25.00 to $21.00 and set a “buy” rating for the company in a report on Tuesday, July 10th. Zacks Investment Research raised shares of American Renal Associates from a “sell” rating to a “hold” rating in a report on Thursday. Finally, Leerink Swann reissued a “market perform” rating and set a $22.00 price objective (down from $27.00) on shares of American Renal Associates in a report on Wednesday, April 25th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $19.40.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Citadel Advisors LLC boosted its holdings in shares of American Renal Associates by 937.3% in the 2nd quarter. Citadel Advisors LLC now owns 128,282 shares of the company’s stock valued at $2,023,000 after buying an additional 115,915 shares during the period. Dimensional Fund Advisors LP boosted its holdings in shares of American Renal Associates by 94.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 495,708 shares of the company’s stock valued at $7,818,000 after buying an additional 240,542 shares during the period. BlackRock Inc. boosted its holdings in shares of American Renal Associates by 33.2% in the 2nd quarter. BlackRock Inc. now owns 816,103 shares of the company’s stock valued at $12,869,000 after buying an additional 203,211 shares during the period. Van Berkom & Associates Inc. boosted its holdings in shares of American Renal Associates by 1.4% in the 2nd quarter. Van Berkom & Associates Inc. now owns 2,540,589 shares of the company’s stock valued at $40,065,000 after buying an additional 34,611 shares during the period. Finally, Spark Investment Management LLC boosted its holdings in shares of American Renal Associates by 43.7% in the 2nd quarter. Spark Investment Management LLC now owns 77,000 shares of the company’s stock valued at $1,214,000 after buying an additional 23,400 shares during the period. 89.39% of the stock is owned by institutional investors and hedge funds.

American Renal Associates traded up $0.19, hitting $21.03, during midday trading on Friday, Marketbeat.com reports. 168,028 shares of the stock were exchanged, compared to its average volume of 157,811. American Renal Associates has a 1 year low of $9.91 and a 1 year high of $24.07. The company has a market capitalization of $676.61 million, a price-to-earnings ratio of 30.65, a price-to-earnings-growth ratio of 1.34 and a beta of 1.96. The company has a debt-to-equity ratio of 5.30, a current ratio of 1.07 and a quick ratio of 1.10.

American Renal Associates Company Profile

American Renal Associates Holdings, Inc operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease.

Featured Article: What is the Book Value of a Share?

Get a free copy of the Zacks research report on American Renal Associates (ARA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for American Renal Associates (NYSE:ARA)

Receive News & Ratings for American Renal Associates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates and related companies with MarketBeat.com's FREE daily email newsletter.